FDA Inspection 1252477 — Devalingam Mahalingam, M.D., Ph.D.
The FDA completed an inspection of Devalingam Mahalingam, M.D., Ph.D. on October 18, 2024 in Chicago, IL. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 2 citations were issued during this inspection. Product area: Drugs.
Inspection Details
- Classification
- Official Action Indicated (OAI) (OAI)
- End Date
- October 18, 2024
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Chicago, IL (United States)
Additional Details
Clinical Investigator (CI)
Citations
| ID | CFR | Description |
|---|---|---|
| 7230 | 21 CFR 50.27(b)(2) | Short form: Oral presentation/signing |
| 7560 | 21 CFR 312.60 | FD-1572, protocol compliance |